Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.
The generally false presumption that they won’t adhere to the regimen is often used to deny coverage for hep C medications.
Weight-based Harvoni treatment cured almost almost all of a small group of very young people.
In a recent study of Gilead’s Epclusa (sofosbuvir/velpatasvir), 92 percent of participants were on dialysis and 29 percent had cirrhosis.
Gilead Sciences has released multiple combo tablets that contain the updated tenofovir, which is linked to improved bone and kidney makers.
The drugs are set to come out in January 2019 with a list price of $24,000 for the most common dose for each.
In a recent study of people whose previous hep C regimen failed to cure their infection, Vosevi cured almost all of them.
Ninety-seven percent of those who took the Gilead regimen after failing a previous therapy were cured in a recent study.
The link between the older interferon treatment and these cancers may be related to the drug’s low hep C cure rate.
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.
Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.
A study in Glasgow provided treatment to those receiving opioid substitution therapy for opioid addiction.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.